Beigene Ltd
ONC311.210USD
-2.460-0.78%
시장 운영 시간 （ET）시세는 15분 지연됩니다
31.44B시가총액
손실P/E TTM
자세한 내용은 Beigene Ltd 회사
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
회사 정보
종목 코드 ONC
회사 이름BeOne Medicines AG
상장일- -
CEOMr. John Victor Oyler
직원 수11000
유형Ordinary Share
회계 연도 종료- -
주소c/o BeOne Medicines I GmbH
도시BASEL
증권 거래소The Toronto Stock Exchange
국가Switzerland
우편 번호4051
전화41616851900
웹사이트
종목 코드 ONC
상장일- -
CEOMr. John Victor Oyler
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
10.89K
--
Mr. Lai Wang
Mr. Lai Wang
Global Head of R&D
Global Head of R&D
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Giancarlo Benelli
Mr. Giancarlo Benelli
Senior Vice President, Head of Europe
Senior Vice President, Head of Europe
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
10.89K
--
Mr. Lai Wang
Mr. Lai Wang
Global Head of R&D
Global Head of R&D
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Giancarlo Benelli
Mr. Giancarlo Benelli
Senior Vice President, Head of Europe
Senior Vice President, Head of Europe
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
수익 분석
통화: USD마지막 업데이트: Sun, Jul 6
통화: USD마지막 업데이트: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
사업별USD
이름
수익
비율
Product
1.09B
97.61%
BRUKINSA
791.66M
70.86%
Tislelizumab
171.16M
15.32%
XGEVA
70.42M
6.30%
BLINCYTO
23.91M
2.14%
기타
-1.03B
-92.23%
지역별USD
이름
수익
비율
United States
567.21M
50.77%
China
399.59M
35.76%
Europe
118.55M
10.61%
ROW
31.92M
2.86%
사업별
지역별
사업별USD
이름
수익
비율
Product
1.09B
97.61%
BRUKINSA
791.66M
70.86%
Tislelizumab
171.16M
15.32%
XGEVA
70.42M
6.30%
BLINCYTO
23.91M
2.14%
기타
-1.03B
-92.23%
주식 보유 통계
마지막 업데이트: Fri, Aug 15
마지막 업데이트: Fri, Aug 15
주주
주주 유형
주주
주주
비율
Amgen Inc
17.22%
Baker Bros. Advisors LP
8.00%
PRIMECAP Management Company
4.62%
Capital International Investors
4.44%
Fidelity Management & Research Company LLC
3.10%
기타
62.62%
주주
주주
비율
Amgen Inc
17.22%
Baker Bros. Advisors LP
8.00%
PRIMECAP Management Company
4.62%
Capital International Investors
4.44%
Fidelity Management & Research Company LLC
3.10%
기타
62.62%
주주 유형
주주
비율
Corporation
17.23%
Investment Advisor
16.67%
Hedge Fund
9.59%
Investment Advisor/Hedge Fund
4.23%
Sovereign Wealth Fund
1.12%
Research Firm
0.63%
Bank and Trust
0.07%
Pension Fund
0.03%
Family Office
0.02%
기타
50.41%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
558
63.29M
57.54%
+456.15K
2025Q1
585
69.06M
63.84%
+3.36M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
2023Q3
632
67.27M
67.88%
-2.05M
2023Q2
655
66.79M
67.58%
-3.13M
2023Q1
655
67.68M
71.16%
-4.10M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Amgen Inc
18.94M
17.28%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.03%
--
--
Mar 31, 2025
PRIMECAP Management Company
5.06M
4.61%
-43.40K
-0.85%
Mar 31, 2025
Capital International Investors
5.09M
4.64%
-1.02M
-16.72%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.36M
3.07%
+1.58M
+88.38%
Mar 31, 2025
HHLR Advisors, Ltd.
1.03M
0.94%
--
--
May 09, 2025
Temasek Holdings Pte. Ltd.
993.75K
0.91%
-531.58K
-34.85%
Mar 31, 2025
T. Rowe Price International Ltd
1.30M
1.19%
-143.22K
-9.92%
Mar 31, 2025
Citadel Advisors LLC
982.16K
0.9%
+665.05K
+209.72%
Mar 31, 2025
Invus Public Equities Advisors, LLC
498.69K
0.46%
-155.03K
-23.72%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
First Trust NYSE Arca Biotechnology Index Fund
3.3%
Tema Oncology ETF
2.75%
VanEck Biotech ETF
2.72%
Global X Aging Population ETF
1.87%
Virtus LifeSci Biotech Products ETF
1.69%
iShares Biotechnology ETF
1.4%
Invesco Nasdaq Biotechnology ETF
1.11%
ProShares Ultra Nasdaq Biotechnology
1.11%
Innovator IBD 50 Fund ETF
0.9%
National Security Emerging Markets Index ETF
0.77%
더 보기
First Trust NYSE Arca Biotechnology Index Fund
비율3.3%
Tema Oncology ETF
비율2.75%
VanEck Biotech ETF
비율2.72%
Global X Aging Population ETF
비율1.87%
Virtus LifeSci Biotech Products ETF
비율1.69%
iShares Biotechnology ETF
비율1.4%
Invesco Nasdaq Biotechnology ETF
비율1.11%
ProShares Ultra Nasdaq Biotechnology
비율1.11%
Innovator IBD 50 Fund ETF
비율0.9%
National Security Emerging Markets Index ETF
비율0.77%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
